FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CBR4-ERBB4

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CBR4-ERBB4
FusionPDB ID: 13417
FusionGDB2.0 ID: 13417
HgeneTgene
Gene symbol

CBR4

ERBB4

Gene ID

84869

2066

Gene namecarbonyl reductase 4erb-b2 receptor tyrosine kinase 4
SynonymsSDR45C1ALS19|HER4|p180erbB4
Cytomap

4q32.3

2q34

Type of geneprotein-codingprotein-coding
Descriptioncarbonyl reductase family member 43-ketoacyl-[acyl-carrier-protein] reductase beta subunit3-oxoacyl-[acyl-carrier-protein] reductaseKAR beta subunitcarbonic reductase 4quinone reductase CBR4short chain dehydrogenase/reductase family 45C member 1receptor tyrosine-protein kinase erbB-4avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4human epidermal growth factor receptor 4proto-oncogene-like protein c-ErbB-4tyrosine kinase-type cell surface receptor HER4v-erb-a erythroblastic
Modification date2020031320200327
UniProtAcc

Q8N4T8

Main function of 5'-partner protein: FUNCTION: The heterotetramer with HSD17B8 has NADH-dependent 3-ketoacyl-acyl carrier protein reductase activity, and thereby plays a role in mitochondrial fatty acid biosynthesis (PubMed:19571038, PubMed:25203508). Within the heterotetramer, HSD17B8 binds NADH; CBR4 binds NADPD (PubMed:25203508). The homotetramer has NADPH-dependent quinone reductase activity (PubMed:19000905). Both homotetramer and the heterotetramer have broad substrate specificity and can reduce 9,10-phenanthrenequinone, 1,4-benzoquinone and various other o-quinones and p-quinones (in vitro) (PubMed:19000905, PubMed:19571038, PubMed:25203508). {ECO:0000269|PubMed:19000905, ECO:0000269|PubMed:19571038, ECO:0000269|PubMed:25203508}.

Q15303

Main function of 5'-partner protein: FUNCTION: Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis. Required for normal cardiac muscle differentiation during embryonic development, and for postnatal cardiomyocyte proliferation. Required for normal development of the embryonic central nervous system, especially for normal neural crest cell migration and normal axon guidance. Required for mammary gland differentiation, induction of milk proteins and lactation. Acts as cell-surface receptor for the neuregulins NRG1, NRG2, NRG3 and NRG4 and the EGF family members BTC, EREG and HBEGF. Ligand binding triggers receptor dimerization and autophosphorylation at specific tyrosine residues that then serve as binding sites for scaffold proteins and effectors. Ligand specificity and signaling is modulated by alternative splicing, proteolytic processing, and by the formation of heterodimers with other ERBB family members, thereby creating multiple combinations of intracellular phosphotyrosines that trigger ligand- and context-specific cellular responses. Mediates phosphorylation of SHC1 and activation of the MAP kinases MAPK1/ERK2 and MAPK3/ERK1. Isoform JM-A CYT-1 and isoform JM-B CYT-1 phosphorylate PIK3R1, leading to the activation of phosphatidylinositol 3-kinase and AKT1 and protect cells against apoptosis. Isoform JM-A CYT-1 and isoform JM-B CYT-1 mediate reorganization of the actin cytoskeleton and promote cell migration in response to NRG1. Isoform JM-A CYT-2 and isoform JM-B CYT-2 lack the phosphotyrosine that mediates interaction with PIK3R1, and hence do not phosphorylate PIK3R1, do not protect cells against apoptosis, and do not promote reorganization of the actin cytoskeleton and cell migration. Proteolytic processing of isoform JM-A CYT-1 and isoform JM-A CYT-2 gives rise to the corresponding soluble intracellular domains (4ICD) that translocate to the nucleus, promote nuclear import of STAT5A, activation of STAT5A, mammary epithelium differentiation, cell proliferation and activation of gene expression. The ERBB4 soluble intracellular domains (4ICD) colocalize with STAT5A at the CSN2 promoter to regulate transcription of milk proteins during lactation. The ERBB4 soluble intracellular domains can also translocate to mitochondria and promote apoptosis. {ECO:0000269|PubMed:10348342, ECO:0000269|PubMed:10353604, ECO:0000269|PubMed:10358079, ECO:0000269|PubMed:10722704, ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:11178955, ECO:0000269|PubMed:11390655, ECO:0000269|PubMed:12807903, ECO:0000269|PubMed:15534001, ECO:0000269|PubMed:15746097, ECO:0000269|PubMed:16251361, ECO:0000269|PubMed:16778220, ECO:0000269|PubMed:16837552, ECO:0000269|PubMed:17486069, ECO:0000269|PubMed:17638867, ECO:0000269|PubMed:19098003, ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:8383326, ECO:0000269|PubMed:8617750, ECO:0000269|PubMed:9135143, ECO:0000269|PubMed:9168115, ECO:0000269|PubMed:9334263}.
Ensembl transtripts involved in fusion geneENST idsENST00000306193, ENST00000509108, 
ENST00000504480, 
ENST00000484474, 
ENST00000342788, ENST00000402597, 
ENST00000436443, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score6 X 4 X 5=12018 X 16 X 8=2304
# samples 617
** MAII scorelog2(6/120*10)=-1
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(17/2304*10)=-3.76053406530461
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: CBR4 [Title/Abstract] AND ERBB4 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CBR4 [Title/Abstract] AND ERBB4 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CBR4(169923222)-ERBB4(212989628), # samples:2
Anticipated loss of major functional domain due to fusion event.CBR4-ERBB4 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CBR4-ERBB4 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneCBR4

GO:0051289

protein homotetramerization

19000905

HgeneCBR4

GO:0051290

protein heterotetramerization

25203508

HgeneCBR4

GO:0055114

oxidation-reduction process

25203508

TgeneERBB4

GO:0007165

signal transduction

10572067

TgeneERBB4

GO:0007169

transmembrane receptor protein tyrosine kinase signaling pathway

10353604|18334220

TgeneERBB4

GO:0016477

cell migration

9135143

TgeneERBB4

GO:0018108

peptidyl-tyrosine phosphorylation

18334220

TgeneERBB4

GO:0046777

protein autophosphorylation

18334220



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr4:169923222/chr2:212989628)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CBR4 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ERBB4 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000306193CBR4chr4169923222-ENST00000436443ERBB4chr2212989628-1239570411545001461
ENST00000306193CBR4chr4169923222-ENST00000342788ERBB4chr2212989628-1244370411545481477
ENST00000306193CBR4chr4169923222-ENST00000402597ERBB4chr2212989628-451970411545181468

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000306193ENST00000436443CBR4chr4169923222-ERBB4chr2212989628-7.97E-050.99992025
ENST00000306193ENST00000342788CBR4chr4169923222-ERBB4chr2212989628-0.0001108520.99988914
ENST00000306193ENST00000402597CBR4chr4169923222-ERBB4chr2212989628-0.0001588530.9998411

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CBR4-ERBB4

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CBR4chr4169923222ERBB4chr2212989628704196VARKKIRVNVVAPVCAGTENKLSSLS

Top

Potential FusionNeoAntigen Information of CBR4-ERBB4 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CBR4-ERBB4_169923222_212989628.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CBR4-ERBB4chr4169923222chr2212989628704HLA-B73:01IRVNVVAPV0.99770.8829514
CBR4-ERBB4chr4169923222chr2212989628704HLA-C06:08IRVNVVAPV0.94720.9862514
CBR4-ERBB4chr4169923222chr2212989628704HLA-C06:02IRVNVVAPV0.07120.9934514
CBR4-ERBB4chr4169923222chr2212989628704HLA-C06:17IRVNVVAPV0.07120.9934514
CBR4-ERBB4chr4169923222chr2212989628704HLA-B67:01APVCAGTENKL0.90180.6431122

Top

Potential FusionNeoAntigen Information of CBR4-ERBB4 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CBR4-ERBB4_169923222_212989628.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0303RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0303ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0303VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0303KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0324RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0324ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0338RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0338ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0338VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0338KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0434RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0466RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0819RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0825RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-0834RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1117RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1117ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1152RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1152ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1186RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1222RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1316RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1331RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1336RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1341RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1367RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1367ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1377RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1385RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1385ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1386RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1386ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1396RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1396ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1401RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1402RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1402ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1403RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1404RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1404ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1405RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1405ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1406RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1406ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1407RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1408RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1408ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1409RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1411RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1411ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1413RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1414RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1414ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1418RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1418ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1419RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1419ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1420RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1420ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1423RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1423ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1424RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1424ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1426RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1428RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1428ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1429RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1429ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1431RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1432RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1434RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1436RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1436ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1438RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1438ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1438VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1439RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1439ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1439VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1440RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1441RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1441ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1442RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1443RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1443ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1444RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1444ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1445RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1445ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1446RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1446ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1447RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1447ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1447VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1447KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1448RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1448ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1448VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1448KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1449RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1449ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1449VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1450RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1450ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1450VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1450KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1451RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1451ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1451VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1452RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1452ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1454RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1455RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1455ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1456RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1456ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1458RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1459RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1459ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1460RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1461RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1461ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1462RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1467RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1468RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1468ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1470RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1470ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1471RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1471ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1475RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1475ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1476RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1476ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1477RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1479RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1479ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1481RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1481ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1482RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1482ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1483RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1483ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1486RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1487RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1488RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1489RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1489ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1490RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1491RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1491ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1493RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1493ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1493VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1493KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1494RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1494ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1495RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1496RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1496ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1497RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1498RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1498ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1498KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1498VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1499RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1499ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB1-1525RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0109RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0109ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0201RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0201ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0201VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0201KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0202RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0202ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0202VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0202KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0204RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0204ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0204VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0204KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0205RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0205ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0205VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0205KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0209RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0209ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0209VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0209KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0210RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0210ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0210VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0210KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0211RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0211ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0211VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0211KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0212RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0212ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0212VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0212KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0213RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0213ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0213VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0213KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0214RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0214ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0214VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0214KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0215RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0215ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0215VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0215KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0216RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0216ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0216VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0216KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0217RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0217ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0217VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0217KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0218RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0218ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0218VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0218KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0219RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0219ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0219VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0219KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0220RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0220ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0220VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0220KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0221RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0221ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0221VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0221KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0222RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0222ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0222VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0222KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0223RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0223ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0223VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0223KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0224RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0224ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0224VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0224KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0225RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0225ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0225VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0225KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0301RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0301ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0301VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0301KKIRVNVVAPVCAGT318
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0303RKKIRVNVVAPVCAG217
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0303ARKKIRVNVVAPVCA116
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0303VARKKIRVNVVAPVC015
CBR4-ERBB4chr4169923222chr2212989628704DRB3-0303KKIRVNVVAPVCAGT318

Top

Fusion breakpoint peptide structures of CBR4-ERBB4

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
8324RVNVVAPVCAGTENCBR4ERBB4chr4169923222chr2212989628704

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CBR4-ERBB4

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN8324RVNVVAPVCAGTEN-4.62591-5.66121
HLA-B52:013W398324RVNVVAPVCAGTEN-7.40283-7.51623
HLA-B52:013W398324RVNVVAPVCAGTEN-5.92265-6.95795
HLA-A11:014UQ28324RVNVVAPVCAGTEN-3.9419-4.9772
HLA-A24:025HGA8324RVNVVAPVCAGTEN-6.10939-7.14469
HLA-B44:053DX88324RVNVVAPVCAGTEN-5.30334-5.41674
HLA-B44:053DX88324RVNVVAPVCAGTEN-2.98945-4.02475
HLA-A02:016TDR8324RVNVVAPVCAGTEN-3.01173-4.04703
HLA-A02:016TDR8324RVNVVAPVCAGTEN-1.9729-2.0863

Top

Vaccine Design for the FusionNeoAntigens of CBR4-ERBB4

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CBR4-ERBB4chr4169923222chr22129896281122APVCAGTENKLCACCAGTGTGTGCAGGAACGGAGAATAAACTGA
CBR4-ERBB4chr4169923222chr2212989628514IRVNVVAPVTTAGAGTGAATGTAGTTGCACCAGTGT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
CBR4-ERBB4chr4169923222chr2212989628015VARKKIRVNVVAPVCTAGCAAGAAAGAAAATTAGAGTGAATGTAGTTGCACCAGTGTGTG
CBR4-ERBB4chr4169923222chr2212989628116ARKKIRVNVVAPVCACAAGAAAGAAAATTAGAGTGAATGTAGTTGCACCAGTGTGTGCAG
CBR4-ERBB4chr4169923222chr2212989628217RKKIRVNVVAPVCAGGAAAGAAAATTAGAGTGAATGTAGTTGCACCAGTGTGTGCAGGAA
CBR4-ERBB4chr4169923222chr2212989628318KKIRVNVVAPVCAGTAGAAAATTAGAGTGAATGTAGTTGCACCAGTGTGTGCAGGAACGG

Top

Information of the samples that have these potential fusion neoantigens of CBR4-ERBB4

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCACBR4-ERBB4chr4169923222ENST00000306193chr2212989628ENST00000342788TCGA-E2-A10E-01A

Top

Potential target of CAR-T therapy development for CBR4-ERBB4

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
TgeneERBB4chr4:169923222chr2:212989628ENST00000342788028652_67501309.0TransmembraneHelical
TgeneERBB4chr4:169923222chr2:212989628ENST00000402597028652_67501299.0TransmembraneHelical
TgeneERBB4chr4:169923222chr2:212989628ENST00000436443027652_67501293.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to CBR4-ERBB4

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CBR4-ERBB4

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
TgeneERBB4C0005586Bipolar Disorder5PSYGENET
TgeneERBB4C0036341Schizophrenia4PSYGENET
TgeneERBB4C0004238Atrial Fibrillation2CTD_human
TgeneERBB4C0235480Paroxysmal atrial fibrillation2CTD_human
TgeneERBB4C2585653Persistent atrial fibrillation2CTD_human
TgeneERBB4C3468561familial atrial fibrillation2CTD_human
TgeneERBB4C0002736Amyotrophic Lateral Sclerosis1ORPHANET
TgeneERBB4C0007114Malignant neoplasm of skin1CTD_human
TgeneERBB4C0016978gallbladder neoplasm1CTD_human
TgeneERBB4C0025202melanoma1CGI;CTD_human
TgeneERBB4C0037286Skin Neoplasms1CTD_human
TgeneERBB4C0153452Malignant neoplasm of gallbladder1CTD_human
TgeneERBB4C3715155AMYOTROPHIC LATERAL SCLEROSIS 191CTD_human;GENOMICS_ENGLAND;UNIPROT